Low relapse rate leads to high concordance of sustained virologic response (SVR) at 12 weeks with SVR at 24 weeks after treatment with ABT-450/ritonavir, ombitasvir, and dasabuvir plus ribavirin in subjects with chronic hepatitis c virus genotype 1 infection in the AVIATOR study

Fred Poordad; Kosh Agarwal; Ziad Younes; Daniel Cohen; Wangang Xie; Thomas Podsadecki

doi:10.1093/cid/ciu865

Low relapse rate leads to high concordance of sustained virologic response (SVR) at 12 weeks with SVR at 24 weeks after treatment with ABT-450/ritonavir, ombitasvir, and dasabuvir plus ribavirin in subjects with chronic hepatitis c virus genotype 1 infection in the AVIATOR study

Fred Poordad, Kosh Agarwal, Ziad Younes, Daniel Cohen, Wangang Xie, Thomas Podsadecki

Research output: Contribution to journal › Article › peer-review

22 Scopus citations

Abstract

In 247 subjects with hepatitis C virus genotype 1 infection treated with the interferon-free regimen of ABT-450/ritonavir, ombitasvir, and dasabuvir plus ribavirin, concordance of a sustained virologic response at 12 and 24 weeks supports the use of the earlier time point as a primary efficacy endpoint for trials of this interferon-free regimen.

Original language	English (US)
Pages (from-to)	608-610
Number of pages	3
Journal	Clinical Infectious Diseases
Volume	60
Issue number	4
DOIs	https://doi.org/10.1093/cid/ciu865
State	Published - Feb 15 2015

Keywords

concordance
direct-acting antivirals
hepatitis C
sustained virologic response

ASJC Scopus subject areas

Microbiology (medical)
Infectious Diseases

Access to Document

10.1093/cid/ciu865

Fingerprint

Dive into the research topics of 'Low relapse rate leads to high concordance of sustained virologic response (SVR) at 12 weeks with SVR at 24 weeks after treatment with ABT-450/ritonavir, ombitasvir, and dasabuvir plus ribavirin in subjects with chronic hepatitis c virus genotype 1 infection in the AVIATOR study'. Together they form a unique fingerprint.

Cite this

Poordad, F., Agarwal, K., Younes, Z., Cohen, D., Xie, W., & Podsadecki, T. (2015). Low relapse rate leads to high concordance of sustained virologic response (SVR) at 12 weeks with SVR at 24 weeks after treatment with ABT-450/ritonavir, ombitasvir, and dasabuvir plus ribavirin in subjects with chronic hepatitis c virus genotype 1 infection in the AVIATOR study. Clinical Infectious Diseases, 60(4), 608-610. https://doi.org/10.1093/cid/ciu865

Low relapse rate leads to high concordance of sustained virologic response (SVR) at 12 weeks with SVR at 24 weeks after treatment with ABT-450/ritonavir, ombitasvir, and dasabuvir plus ribavirin in subjects with chronic hepatitis c virus genotype 1 infection in the AVIATOR study. / Poordad, Fred; Agarwal, Kosh; Younes, Ziad et al.
In: Clinical Infectious Diseases, Vol. 60, No. 4, 15.02.2015, p. 608-610.

Research output: Contribution to journal › Article › peer-review

Poordad, F, Agarwal, K, Younes, Z, Cohen, D, Xie, W & Podsadecki, T 2015, 'Low relapse rate leads to high concordance of sustained virologic response (SVR) at 12 weeks with SVR at 24 weeks after treatment with ABT-450/ritonavir, ombitasvir, and dasabuvir plus ribavirin in subjects with chronic hepatitis c virus genotype 1 infection in the AVIATOR study', Clinical Infectious Diseases, vol. 60, no. 4, pp. 608-610. https://doi.org/10.1093/cid/ciu865

Poordad F, Agarwal K, Younes Z, Cohen D, Xie W, Podsadecki T. Low relapse rate leads to high concordance of sustained virologic response (SVR) at 12 weeks with SVR at 24 weeks after treatment with ABT-450/ritonavir, ombitasvir, and dasabuvir plus ribavirin in subjects with chronic hepatitis c virus genotype 1 infection in the AVIATOR study. Clinical Infectious Diseases. 2015 Feb 15;60(4):608-610. doi: 10.1093/cid/ciu865

Poordad, Fred ; Agarwal, Kosh ; Younes, Ziad et al. / Low relapse rate leads to high concordance of sustained virologic response (SVR) at 12 weeks with SVR at 24 weeks after treatment with ABT-450/ritonavir, ombitasvir, and dasabuvir plus ribavirin in subjects with chronic hepatitis c virus genotype 1 infection in the AVIATOR study. In: Clinical Infectious Diseases. 2015 ; Vol. 60, No. 4. pp. 608-610.

@article{621c24af5501435e94e5d78a873f9769,

title = "Low relapse rate leads to high concordance of sustained virologic response (SVR) at 12 weeks with SVR at 24 weeks after treatment with ABT-450/ritonavir, ombitasvir, and dasabuvir plus ribavirin in subjects with chronic hepatitis c virus genotype 1 infection in the AVIATOR study",

abstract = "In 247 subjects with hepatitis C virus genotype 1 infection treated with the interferon-free regimen of ABT-450/ritonavir, ombitasvir, and dasabuvir plus ribavirin, concordance of a sustained virologic response at 12 and 24 weeks supports the use of the earlier time point as a primary efficacy endpoint for trials of this interferon-free regimen.",

keywords = "concordance, direct-acting antivirals, hepatitis C, sustained virologic response",

author = "Fred Poordad and Kosh Agarwal and Ziad Younes and Daniel Cohen and Wangang Xie and Thomas Podsadecki",

note = "Publisher Copyright: {\textcopyright} The Author 2014.",

year = "2015",

month = feb,

day = "15",

doi = "10.1093/cid/ciu865",

language = "English (US)",

volume = "60",

pages = "608--610",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "4",

}

TY - JOUR

T1 - Low relapse rate leads to high concordance of sustained virologic response (SVR) at 12 weeks with SVR at 24 weeks after treatment with ABT-450/ritonavir, ombitasvir, and dasabuvir plus ribavirin in subjects with chronic hepatitis c virus genotype 1 infection in the AVIATOR study

AU - Poordad, Fred

AU - Agarwal, Kosh

AU - Younes, Ziad

AU - Cohen, Daniel

AU - Xie, Wangang

AU - Podsadecki, Thomas

PY - 2015/2/15

Y1 - 2015/2/15

N2 - In 247 subjects with hepatitis C virus genotype 1 infection treated with the interferon-free regimen of ABT-450/ritonavir, ombitasvir, and dasabuvir plus ribavirin, concordance of a sustained virologic response at 12 and 24 weeks supports the use of the earlier time point as a primary efficacy endpoint for trials of this interferon-free regimen.

AB - In 247 subjects with hepatitis C virus genotype 1 infection treated with the interferon-free regimen of ABT-450/ritonavir, ombitasvir, and dasabuvir plus ribavirin, concordance of a sustained virologic response at 12 and 24 weeks supports the use of the earlier time point as a primary efficacy endpoint for trials of this interferon-free regimen.

KW - concordance

KW - direct-acting antivirals

KW - hepatitis C

KW - sustained virologic response

UR - https://www.scopus.com/pages/publications/84922372748

UR - https://www.scopus.com/inward/citedby.url?scp=84922372748&partnerID=8YFLogxK

U2 - 10.1093/cid/ciu865

DO - 10.1093/cid/ciu865

M3 - Article

C2 - 25365973

AN - SCOPUS:84922372748

SN - 1058-4838

VL - 60

SP - 608

EP - 610

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

IS - 4

ER -

Low relapse rate leads to high concordance of sustained virologic response (SVR) at 12 weeks with SVR at 24 weeks after treatment with ABT-450/ritonavir, ombitasvir, and dasabuvir plus ribavirin in subjects with chronic hepatitis c virus genotype 1 infection in the AVIATOR study

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this